Sector News

How Venezuela's meltdown delivered a mega-hit to Big Pharma: Reuters

March 7, 2016
Life sciences

One word popped up over and over when Big Pharma reported earnings last month: Venezuela. The association wasn’t positive. Executives blamed losses there for hundreds of millions in currency-related hits to their financials.

Novartis saw net income drop 18% year-over-year, partly because of “exceptional charges in 2015 mostly related to our Venezuela subsidiaries,” Novartis CFO Harry Kirsch said during the Swiss drugmaker’s Q4 earnings call–charges that so far amounted to $337 million.

Sanofi EVP Peter Guenter, who oversees emerging markets, called a €240 million foreign exchange loss in the country “the Venezuela effect,” and said the company sees another €100 million to come.

Pfizer says it’s expecting a $800 million currency hit from Venezuela–“roughly the same size as 2015,” according to CEO Ian Read, when the Venezuela problem reduced 2015 earnings by $0.07 per share.

It’s no secret that the Venezuelan economy has been in the tank, and Sanofi, in particular, has a big presence in there, partly in thanks to its 2012 Genfar acquisition. Novartis and another company that experienced the “Venezuela effect,” Bayer, have substantial sales there, too.

But what happened, exactly? As pharma has been forced to do in other countries suffering debt crises–Greece, for one–these companies took payments worth much less than Venezuela’s outstanding bills.

But in Venezuela, the mechanism was somewhat different, Reuters reports. In one example, Novartis was paid in the local currency, bolivars, for their products, and currency controls effectively trapped that cash. So, the companies negotiated to use those bolivars to buy bonds issued by the state oil company, PDVSA, denominated in U.S. dollars.

The exchange rate to dollars in that deal was, to put it mildly, poor, thanks to a recent devaluation of the currency. Hence losses via foreign exchange. But there was another loss. When the company sold the PDVSA bonds, it was for about 37 cents on the dollar, Reuters notes, for another $127 million hit.

The other drugmakers engineered similar deals, and sold the bonds for as little as a third of their face value. Pharma’s bills in Greece were also paid in bonds, via a special bond issue, but those bonds were euro-denominated. The companies involved there–including Roche–sold those bonds at a big discount.

Pharma companies are still holding onto bolivars, and they’re forced to take bolivars for ongoing drug bills, despite the deteriorating currency. Getting that cash out of Venezuela will trigger more losses. Pfizer’s $800 million “negative impact” related to Venezuela in both 2015 and projected for 2016 stems from a change to a 200 bolivars-to-the-dollar exchange rate.

“[W]e thought that the timing of that adjustment was appropriate, given oil prices, given what’s going on in Venezuela economically, given the dollars that are coming out of Venezuela,” Read said during the Q4 earnings call, adding that the previous exchange rate was 6.3 to one. He didn’t mention oil bonds as playing a role.

CFO Frank D’Amelio says Pfizer is optimistic about Venezuela in the long run. “[W]hen Venezuela passes through this crisis and they re-establish a normal economy, we would expect Venezuela to grow back to be between 200 and 400 million a year,” D’Amelio said.

And pharma’s outlook for Latin America in general is strong enough that drugmakers are scouting acquisitions there. Sanofi, Pfizer and Abbott Laboratories were rumored to be weighing a buyout of Mexico-based Rimsa last year until Teva Pharmaceutical snapped up the company for $2.3 billion.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”